Literature DB >> 28133930

In vitro evaluation of Selective Inhibitors of Nuclear Export (SINE) drugs KPT-185 and KPT-335 against canine mammary carcinoma and transitional cell carcinoma tumor initiating cells.

J E Grayton1, T Miller2, H Wilson-Robles2.   

Abstract

Entities:  

Keywords:  cell signalling; in vitro models; oncology; stem cells; tumour biology

Mesh：

Substances：

Year:  2017        PMID： 28133930     DOI： 10.1111/vco.12289

Source DB:  PubMed          Journal:  Vet Comp Oncol        ISSN： 1476-5810            Impact factor:   2.613


× No keyword cloud information.
  5 in total

Review 1.  The nuclear export protein XPO1 - from biology to targeted therapy.

Authors:  Asfar S Azmi; Mohammed H Uddin; Ramzi M Mohammad
Journal:  Nat Rev Clin Oncol       Date:  2020-11-10       Impact factor: 66.675

Review 2.  Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses.

Authors:  Jennifer A Pickens; Ralph A Tripp
Journal:  Viruses       Date:  2018-01-21       Impact factor: 5.048

Review 3.  Characteristics and Applications of Canine In Vitro Models of Bladder Cancer in Veterinary Medicine: An Up-to-Date Mini Review.

Authors:  Łukasz Nowak; Wojciech Krajewski; Bartosz Małkiewicz; Tomasz Szydełko; Aleksandra Pawlak
Journal:  Animals (Basel)       Date:  2022-02-19       Impact factor: 2.752

4.  The selective inhibitor of nuclear export (SINE) verdinexor exhibits biologic activity against canine osteosarcoma cell lines.

Authors:  Justin T Breitbach; Darian S Louke; Savannah J Tobin; Mauria R Watts; Alexander E Davies; Joelle M Fenger
Journal:  Vet Comp Oncol       Date:  2021-01-26       Impact factor: 2.613

5.  Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma.

Authors:  Abbey R Sadowski; Heather L Gardner; Antonella Borgatti; Heather Wilson; David M Vail; Joshua Lachowicz; Christina Manley; Avenelle Turner; Mary K Klein; Angharad Waite; Alexandra Sahora; Cheryl A London
Journal:  BMC Vet Res       Date:  2018-08-24       Impact factor: 2.741
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.